Blockchain Registration Transaction Record

Lantern Pharma's AI Platform Challenges Broken Drug Development Model

Lantern Pharma's AI platform challenges traditional drug development at BioNTX summit. CEO Panna Sharma advocates for AI-driven oncology solutions to accelerate cancer treatment innovation and reduce costs.

This news matters because it highlights a fundamental shift in how cancer treatments are developed, potentially accelerating the delivery of life-saving therapies to patients. Traditional drug development can take over a decade and cost billions, with high failure rates that ultimately delay critical treatments. Lantern Pharma's AI-driven approach could dramatically reduce both time and cost while increasing success rates, meaning new oncology drugs could reach patients faster and at lower costs. For cancer patients and their families, this represents hope for more timely access to innovative treatments. For the healthcare system, it promises more efficient use of research funding and potentially lower drug prices. The adoption of AI in biopharma could revolutionize an industry critical to global health, making this development significant not just for investors but for anyone affected by cancer.